VRTX
NASDAQ · Biotechnology
Vertex Pharmaceuticals Inc
$477.92
+19.11 (+4.17%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 11.07B | 9.77B | 17.79B | 15.93B | 17.43B |
| Net Income | -538,071,338 | -427,379,934 | 1.52B | 1.35B | 1.92B |
| EPS | — | — | — | — | — |
| Profit Margin | -4.9% | -4.6% | 8.5% | 8.5% | 11.0% |
| Rev Growth | +13.3% | +13.3% | +12.7% | -6.3% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 442.58M | 442.58M | 14.11B | 13.83B | 14.35B |
| Total Equity | 61.47B | 61.47B | 86.73B | 91.42B | 88.18B |
| D/E Ratio | 0.01 | 0.01 | 0.16 | 0.15 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -102,779,709 | -86,171,320 | 2.57B | 2.28B | 2.59B |
| Free Cash Flow | — | — | 2.35B | 1.35B | 2.40B |